Skip to main content

Mouse CD30 Ligand/TNFSF8 Antibody

R&D Systems, part of Bio-Techne | Catalog # AF732

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
AF732
AF732-SP

Key Product Details

Species Reactivity

Mouse

Applications

Neutralization, Western Blot

Label

Unconjugated

Antibody Source

Polyclonal Goat IgG

Product Specifications

Immunogen

Mouse myeloma cell line NS0-derived recombinant mouse CD30 Ligand/TNFSF8
Gln68-Asp239
Accession # P32972

Specificity

Detects mouse CD30 Ligand/TNFSF8 in direct ELISAs and Western blots. In direct ELISAs and Western blots, approximately 5% cross‑reactivity with recombinant human CD30 Ligand is observed.

Clonality

Polyclonal

Host

Goat

Isotype

IgG

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Scientific Data Images for Mouse CD30 Ligand/TNFSF8 Antibody

IL-6 Secretion Induced by CD30 Ligand/TNFSF8 and Neutralization by Mouse CD30 Ligand/TNFSF8 Antibody.

IL-6 Secretion Induced by CD30 Ligand/TNFSF8 and Neutralization by Mouse CD30 Ligand/TNFSF8 Antibody.

In the presence of a cross-linking antibody, Mouse polyHistidine Monoclonal Antibody (10 µg/mL, Catalog # MAB050), Recombinant Mouse CD30 Ligand/TNFSF8 (Catalog # 732-CL) stimulates IL-6 secretion in the HDLM human Hodgkin’s lymphoma cell line in a dose-dependent manner (orange line), as measured by the Human IL-6 Quantikine ELISA Kit (Catalog # D6050). Under these conditions, IL-6 secretion elicited by Recombinant Mouse CD30 Ligand/TNFSF8 (500 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Mouse CD30 Ligand/TNFSF8 Antigen Affinity-purified Poly-clonal Antibody (Catalog # AF732). The ND50 is typically 3-10 µg/mL.

Applications for Mouse CD30 Ligand/TNFSF8 Antibody

Application
Recommended Usage

Western Blot

0.1 µg/mL
Sample: Recombinant Mouse CD30 Ligand/TNFSF8 (Catalog # 732-CL)

Neutralization

Measured by its ability to neutralize CD30 Ligand/TNFSF8-induced IL‑6 secretion in the HDLM human Hodgkin’s lymphoma cell line. The Neutralization Dose (ND50) is typically 3-10 µg/mL in the presence of 500 ng/mL Recombinant Mouse CD30 Ligand/TNFSF8 and 10 µg/mL of a cross-linking antibody, Mouse polyHistidine Monoclonal Antibody.

Formulation, Preparation, and Storage

Purification

Antigen Affinity-purified

Reconstitution

Reconstitute at 0.2 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: CD30 Ligand/TNFSF8

CD30 Ligand (CD30L)/TNFSF8 is a type II membrane protein belonging to the TNF superfamily. CD30L is expressed on the cell surface of activated T cells, B cells, and monocytes. The protein is also constitutively expressed on granulocytes and medullary thymic epithelial cells. The specific receptor for CD30L is CD30/TNFRSF8, a type I transmembrane glycoprotein belonging to the TNF receptor superfamily. CD30 was originally identified as a cell surface antigen of Hodgkin's and Reed-Sternberg cells using the monoclonal antibody Ki-1. CD30 is also expressed on different non-Hodgkin's lymphomas, virus-infected T and B cells, and on normal T and B cells after activation. Among T cells, CD30 is preferentially expressed on a subset of T cells producing Th2-type cytokines and on CD4+/CD8+ thymocytes that coexpress CD45RO and IL-4 receptor. CD30 ligation by CD30L mediates pleiotropic effects including cell proliferation, activation, differentiation and cell death by apoptosis. CD30 can act as a co‑stimulatory molecule in thymic negative selection and may also play a critical role in the pathophysiology of Hodgkin's disease and other CD30+ lymphomas.

References

  1. Brunangelo, F. et al. (1995) Blood 85:1.
  2. Gruss, H-J. and F. Herrmann (1996) Leukemia and Lymphoma 20:397.
  3. Chiarle, R. et al. (1999) J. Immunol. 163:194.

Alternate Names

CD153, CD30L, TNFSF8

Entrez Gene IDs

944 (Human); 21949 (Mouse)

Gene Symbol

TNFSF8

UniProt

Additional CD30 Ligand/TNFSF8 Products

Product Documents for Mouse CD30 Ligand/TNFSF8 Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Mouse CD30 Ligand/TNFSF8 Antibody

For research use only

Loading...
Loading...
Loading...
Loading...